VKTX Viking Therapeutics, Inc.

Nasdaq vikingtherapeutics.com


$ 37.76 $ -0.31 (-0.81 %)    

Monday, 17-Nov-2025 15:44:49 EST
QQQ $ 601.75 $ -4.38 (-0.72 %)
DIA $ 465.89 $ -5.15 (-1.09 %)
SPY $ 664.28 $ -5.45 (-0.81 %)
TLT $ 89.12 $ 0.04 (0.04 %)
GLD $ 370.78 $ -3.22 (-0.86 %)
$ 39.11
$ 37.80
$ 37.73 x 77
$ 37.78 x 7
$ 36.88 - $ 38.69
$ 18.92 - $ 56.25
3,432,305
na
4.42B
$ 1.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-22-2025 09-30-2025 10-Q
2 07-23-2025 06-30-2025 10-Q
3 04-24-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 10-23-2024 09-30-2024 10-Q
6 07-24-2024 06-30-2024 10-Q
7 04-25-2024 03-31-2024 10-Q
8 02-07-2024 12-31-2023 10-K
9 10-25-2023 09-30-2023 10-Q
10 07-26-2023 06-30-2023 10-Q
11 04-26-2023 03-31-2023 10-Q
12 02-10-2023 12-31-2022 10-K
13 10-26-2022 09-30-2022 10-Q
14 07-27-2022 06-30-2022 10-Q
15 04-27-2022 03-31-2022 10-Q
16 02-09-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 07-28-2021 06-30-2021 10-Q
19 04-28-2021 03-31-2021 10-Q
20 02-17-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 07-29-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 03-13-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-07-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-21-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 druckenmiller-opens-position-in-amazon-closes-microsoft--heres-more-of-duquesnes-biggest-q3-moves

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven...

 canaccord-genuity-maintains-buy-on-viking-therapeutics-raises-price-target-to-107

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target fro...

 amd-oklo-applovin-corp-viking-therapeutics-and-novo-nordisk-why-these-5-stocks-are-on-investors-radars-today

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 50...

 viking-therapeutics-data-from-phase-2-venture-clinical-study-of-vk2735-demonstrated-improvement-in-cardiometabolic-parameters-in-participants-reductions-in-prevalence-of-prediabetes-and-mets-at-week-13

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the developm...

 druckenmillers-viking-trade-just-hit-a-golden-cross--and-a-sweet-36-gain

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden C...

 jim-cramer-says-take-a-pass-on-this-tech-stock-wont-go-near-oils

Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profra...

 viking-therapeutics-announces-that-its-vv2735-obesity-program-will-be-featured-in-two-poster-presentations-at-obesityweek-2025-in-atlanta

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic StatusAdditional Po...

 canaccord-genuity-initiates-coverage-on-viking-therapeutics-with-buy-rating-announces-price-target-of-106

Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announce...

 jp-morgan-maintains-overweight-on-viking-therapeutics-lowers-price-target-to-75

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target fr...

 why-is-viking-therapeutics-stock-rising-today

Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings an...

 morgan-stanley-maintains-overweight-on-viking-therapeutics-raises-price-target-to-102

Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and raises the price target...

 viking-therapeutics-q3-eps-081-misses-072-estimate

Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of...

 retail-investors-top-stocks-with-earnings-this-week-tesla-netflix-intel-and-more

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

 hc-wainwright--co-reiterates-buy-on-viking-therapeutics-maintains-102-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ: VKTX) with a Buy and maintains $102...

 btig-reiterates-buy-on-viking-therapeutics-maintains-125-price-target

BTIG analyst Justin Zelin reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $125 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION